Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Bought by Golden State Equity Partners

Golden State Equity Partners raised its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 21.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 201,225 shares of the biopharmaceutical company’s stock after buying an additional 34,960 shares during the period. Golden State Equity Partners’ holdings in Sangamo Therapeutics were worth $109,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of SGMO. Acadian Asset Management LLC boosted its holdings in Sangamo Therapeutics by 3.7% in the third quarter. Acadian Asset Management LLC now owns 2,927,769 shares of the biopharmaceutical company’s stock valued at $1,753,000 after purchasing an additional 105,789 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 129,811 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new stake in Sangamo Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC lifted its stake in Sangamo Therapeutics by 103.9% in the fourth quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 92,002 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sangamo Therapeutics by 10.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company’s stock valued at $406,000 after purchasing an additional 62,465 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on SGMO. Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Finally, StockNews.com assumed coverage on Sangamo Therapeutics in a report on Saturday. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.67.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.52 on Monday. The stock’s 50-day moving average is $0.77 and its two-hundred day moving average is $0.59. Sangamo Therapeutics, Inc. has a 1 year low of $0.29 and a 1 year high of $1.78. The firm has a market cap of $107.44 million, a price-to-earnings ratio of -0.35 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. The firm had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $8.96 million. As a group, research analysts predict that Sangamo Therapeutics, Inc. will post -0.54 EPS for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.